首页> 美国卫生研究院文献>Indian Journal of Clinical Biochemistry >Diagnostic Significance of CA15-3 with Combination of HER-2eu Values at 85th Percentiles in Breast Cancer
【2h】

Diagnostic Significance of CA15-3 with Combination of HER-2eu Values at 85th Percentiles in Breast Cancer

机译:CA15-3与HER-2 / neu值相结合对乳腺癌第85个百分位数的诊断意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The human epidermal receptor-2eu (HER-2eu) oncogene encodes a transmembrane tyrosine kinase receptor. This molecule could have a diagnostic value since the extracellular domain of c-erbB-2 (HER-2) transmembrane is shed into the blood as a circulating antigen. The diagnostic value of serum HER-2eu was calculated along with the conventional marker carbohydrate antigen 15-3 (CA15-3) and carcinoembryonic antigen (CEA) at 85th percentiles. Serum levels of breast carcinoma antigens HER-2eu, CEA and CA15-3 were determined in 175 normal individuals and 268 malignant patients. The soluble form of serum HER-2eu, CEA and CA15-3 was assayed by enzyme linked immunosorbent assay in control and breast cancer patients prior to treatment. Serum levels of the tested tumor markers HER-2eu and CA15-3 and CEA were significantly higher in cancer patients compared to controls. At 85th percentile the sensitivity of HER-2eu was 51.12 %; the specificity was 86.29 % and the overall accuracy was 64.56 %. The sensitivity of CA15-3 was 73.13 %; the specificity was 85.14 % and the overall accuracy was 77.88 %. The sensitivity of the combined testing was 82.84 %; the specificity was 73.71 % and the overall accuracy was 80.01 %. The sensitivity and the overall accuracy of combined testing were higher than those of HER-2eu and CA15-3 testing single. The combined testing of HER-2eu and CA15-3 can increase the sensitivity and overall accuracy of breast cancer diagnosis. The results of this study suggest that the use of multiple tumor markers may be employed as combination and at 85th percentiles to assess the prognosis.
机译:人表皮受体2 / neu(HER-2 / neu)癌基因编码跨膜酪氨酸激酶受体。该分子可能具有诊断价值,因为c-erbB-2(HER-2)跨膜的胞外域作为循环抗原进入了血液。计算了血清HER-2 / neu的诊断价值,以及传统的标记碳水化合物抗原15-3(CA15-3)和癌胚抗原(CEA)在第85个百分点。在175名正常人和268名恶性患者中测定了乳腺癌抗原HER-2 / neu,CEA和CA15-3的血清水平。在治疗前,通过酶联免疫吸附法在对照组和乳腺癌患者中测定血清HER-2 / neu,CEA和CA15-3的可溶形式。与对照组相比,癌症患者的血清肿瘤标记物HER-2 / neu,CA15-3和CEA的血清水平显着更高。在第85个百分点,HER-2 / neu的敏感性为51.12%;特异性为86.29%,总体准确度为64.56%。 CA15-3的敏感性为73.13%;特异性为85.14%,总体准确度为77.88%。组合测试的灵敏度为82.84%;特异性为73.71%,总体准确度为80.01%。组合测试的敏感性和整体准确性高于HER-2 / neu和CA15-3单一测试。 HER-2 / neu和CA15-3的组合测试可以提高乳腺癌诊断的敏感性和整体准确性。这项研究的结果表明,可以将多种肿瘤标志物组合使用,并以第85个百分位来评估预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号